探测与人类诺西/孤儿素FQ受体结合的非激剂:一个分子建模研究
Matteo Gozzi1, Davide Malfacini2, Valentina Albanese3
1Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara 44121 Ferrara Italy antonella.ciancetta@unife.it.
RSC medicinal chemistry
|January 10, 2025
概括
研究人员开发了一种计算方法来预测小分子激动剂如何与nociceptin/orphaninFQ (NOP) 受体结合. 这种方法有助于设计没有阿片类药物副作用的新型止痛药.
科学领域:
- 药理学 药理学是指药理学的学科.
- 结构生物学 结构生物学
- 计算化学计算化学
背景情况:
- 诺西塞/孤儿素FQ (NOP) 受体是开发具有比传统阿片类药物更少副作用的止痛药的关键标.
- 现有的NOP受体结构数据包括其内源性激动剂和对抗剂的复合物,但活性状态激动剂的结合仍然不清楚.
研究的目的:
- 开发和验证一个计算协议,用于预测NOP受体活性状态下的小分子激动剂结合模式.
- 为NOP受体药物开发提供选择性小分子激动剂的结合机制的见解.
主要方法:
- 利用NOP受体现有的X射线和冷EM结构.
- 采用了结合分子对接和短分子动力学 (MD) 模拟的计算协议.
- 使用N/OFQ(1-13)-NH2作为验证的参考化合物.
主要成果:
- 开发的协议成功地为小分子激动剂提出了可重复和稳定的结合模式.
- 预测的结合模式与化,嵌入膜的NOP受体的活性状态一致.
- 结果与已确定的结构-活动关系 (SAR) 数据保持一致.
结论:
- 该计算协议提供了一种可靠的方法,用于阐明小分子激动剂在NOP受体上的结合.
- 这种方法可以指导新型NOP受体向止痛药的设计.
- 对NOP受体活性状态的进一步结构洞察对于药物发现至关重要.
相关概念视频
Opioid Receptors: Overview
501
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
501
Drug-Receptor Interaction: Agonist
2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K
The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
Drug-Receptor Interactions
4.8K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
4.8K
Drug-Receptor Interaction: Antagonist
2.7K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
2.7K
Analgesia and Pain Management
490
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
490


